First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

被引：0
|
作者：
Weili Sun
Huaying Liu
Young Kim
Nicole Karras
Anna Pawlowska
Debbie Toomey
Wade Kyono
Paul Gaynon
Joseph Rosenthal
Anthony Stein
机构：
[1] City of Hope National Medical Center,Department of Pediatrics
[2] Southern Medical University,Department of Pediatrics, Nanfang Hospital
[3] City of Hope National Medical Center,Department of Pathology
[4] University of Hawaii,Department of Pediatrics, Kapiolani Medical Center for Women and Children
[5] University of Southern California,Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles
[6] City of Hope National Medical Center,Department of Hematology and Hematopoietic Cell Transplantation
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Pediatric; BPDCN; SL-401; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases
    Sun, Weili
    Liu, Huaying
    Kim, Young
    Karras, Nicole
    Pawlowska, Anna
    Toomey, Debbie
    Kyono, Wade
    Gaynon, Paul
    Rosenthal, Joseph
    Stein, Anthony
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [2] TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY
    Vinti, Luciana
    Pemmaraju, Naveen
    Pawlowska, Anna
    Cuglievan, Branko
    Lasky, Joseph
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony
    Meshinchi, Soheil
    Mullen, Craig
    Mughal, Tariq
    Angelucci, Emanuele
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S195 - S196
  • [3] Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm
    Economides, Minas P.
    McCue, Deborah
    Lane, Andrew A.
    Pemmaraju, Naveen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 941 - 946
  • [4] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy
    Pemmaraju, Naveen
    Cuglievan, Branko
    Lasky, Joseph L., III
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony S.
    Pawlowska, Anna B.
    BLOOD, 2021, 138
  • [5] Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
    Frankel, Arthur E.
    Woo, Jung H.
    Ahn, Chul
    Pemmaraju, Naveen
    Medeiros, Bruno C.
    Carraway, Hetty E.
    Frankfurt, Olga
    Forman, Stephen J.
    Yang, Xuezhong A.
    Konopleva, Marina
    Garnache-Ottou, Francine
    Angelot-Delettre, Fanny
    Brooks, Christopher
    Szarek, Michael
    Rowinsky, Eric
    BLOOD, 2014, 124 (03) : 385 - 392
  • [6] Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial
    Pemmaraju, Naveen
    Lane, Andrew
    Sweet, Kendra
    Stein, Anthony
    Vasu, Sumithira
    Blum, William
    Rizzieri, David
    Wang, Eunice
    Duvic, Madeleine
    Brooks, Christopher
    Sloan, J. Mark
    Rosenblat, Todd
    Akilov, Oleg
    Mughal, Tariq
    Lancet, Jeffrey
    Kantarjian, Hagop
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S209 - S210
  • [7] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123Targeted Therapy
    Pemmaraju, Naveen
    Cuglievan, Branko
    Lasky, Joseph
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony S.
    Meshinchi, Soheil
    Mullen, Craig
    Angelucci, Emanuele
    Vinti, Luciana
    Mughal, Tariq I.
    Pawlowska, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S244 - S245
  • [8] Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Sweet, Kendra L.
    Lane, Andrew A.
    Stein, Anthony S.
    Vasu, Sumithira
    Blum, William
    Rizzieri, David A.
    Wang, Eunice S.
    Duvic, Madeleine
    Aung, Phyu
    Shubert, Danielle
    Spence, Sharon
    Shemesh, Shay
    Chen, Janice
    Brooks, Christopher
    Bergstein, Ivan
    McDonald, Peter
    Goswami, Trishna
    Sloan, John Mark
    Lancet, Jeffrey E.
    Kantarjian, Hagop M.
    Konopleva, Marina
    BLOOD, 2017, 130
  • [9] The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells
    Angelot-Delettre, Fanny
    Frankel, Arthur E.
    Liu, Jen Sing
    Seilles, Estelle
    Biichle, Sabeha
    Drenou, Bernard
    Jacobson, Mark L.
    Cirrito, Thomas P.
    Yazid, Arkam
    Deconinck, Eric
    Brooks, Christopher L.
    Saas, Philippe
    Ottou, Francine Garnache
    BLOOD, 2011, 118 (21) : 1111 - 1111
  • [10] The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe
    Platzbecker, Uwe
    Angelucci, Emanuele
    Montesinos, Pau
    Lemoni, Roberto M.
    Spyridonidis, Alexandros
    Casariego, Joaquin
    Mughal, Tariq I.
    Mohty, Mohamad
    BLOOD, 2021, 138
12345